$125M Stock Sale Priced at $7.75, Just Above the Last Close
DTIL has more than doubled off its 52-week low of $3.53.
Summary
Precision priced a $125 million underwritten offering of 10,235,077 common shares at $7.75 and pre-funded warrants for 5,893,964 shares at $7.749995, essentially flat to the $7.73 last price. The raise is large next to the company's roughly $227 million market value, so existing holders take meaningful dilution even though the pricing shows no discount. New and existing specialist biotech funds — First Light, MPM BioImpact, Bleichroeder, Lynx1, Readout, Aberdeen and Driehaus — are on the ticket, which is a decent demand read. Proceeds fund PBGENE-HBV and PBGENE-DMD development plus working capital, adding to the $108.0 million of cash and management-guided runway through 2028 reported with Q3 results on November 3. The offering is expected to close on or about November 6, subject to customary conditions, with TD Cowen and Guggenheim as joint book-running managers.
At the time of this announcement, DTIL was trading at $7.73 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $226.8M. The 52-week trading range was $3.53 to $9.62. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: BusinessWire.